|
Volumn 69, Issue 4, 2017, Pages 463-464
|
Cangrelor Use Since FDA Approval: A Single-Center, Real-World Experience at a Tertiary Care Hospital
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CANGRELOR;
ADENOSINE PHOSPHATE;
PURINERGIC P2Y RECEPTOR ANTAGONIST;
ACUTE CORONARY SYNDROME;
BLEEDING;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDICATION;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LETTER;
PERCUTANEOUS CORONARY INTERVENTION;
PHASE 3 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
AGED;
ANALOGS AND DERIVATIVES;
CORONARY ARTERY DISEASE;
FEMALE;
INTRAOPERATIVE PERIOD;
INTRAVENOUS DRUG ADMINISTRATION;
MALE;
MIDDLE AGED;
TERTIARY CARE CENTER;
UNITED STATES;
ADENOSINE MONOPHOSPHATE;
AGED;
CORONARY ARTERY DISEASE;
DRUG APPROVAL;
FEMALE;
HUMANS;
INJECTIONS, INTRAVENOUS;
INTRAOPERATIVE PERIOD;
MALE;
MIDDLE AGED;
PERCUTANEOUS CORONARY INTERVENTION;
PURINERGIC P2Y RECEPTOR ANTAGONISTS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TERTIARY CARE CENTERS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 85007480717
PISSN: 07351097
EISSN: 15583597
Source Type: Journal
DOI: 10.1016/j.jacc.2016.11.017 Document Type: Letter |
Times cited : (21)
|
References (3)
|